What’s Jaguar Health Inc (NASDAQ:JAGX) Upside After This Short Interest Decrease?

Jaguar Health, Inc. (NASDAQ:JAGX) Logo

The stock of Jaguar Health Inc (NASDAQ:JAGX) registered a decrease of 26.93% in short interest. JAGX’s total short interest was 99,300 shares in September as published by FINRA. Its down 26.93% from 135,900 shares, reported previously. With 321,400 shares average volume, it will take short sellers 0 days to cover their JAGX’s short positions. The short interest to Jaguar Health Inc’s float is 0.49%.

It closed at $1.33 lastly. It is up 97.61% since September 13, 2018 and is downtrending. It has underperformed by 97.61% the S&P500.

Napo Pharmaceuticals, Inc., a human health company, focuses on developing and commercializing novel gastrointestinal prescription products from plants. The company has market cap of $8.12 million. The Company’s products include Mytesi, an FDA approved product for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. It currently has negative earnings. Napo Pharmaceuticals, Inc. was formerly known as PS Pharmaceuticals, Inc.

More notable recent Jaguar Health, Inc. (NASDAQ:JAGX) news were published by: Benzinga.com which released: “12 Healthcare Stocks Moving In Thursday’s Pre-Market Session – Benzinga” on August 22, 2019, also Seekingalpha.com with their article: “DRYS, SINA among premarket gainers – Seeking Alpha” published on August 19, 2019, Seekingalpha.com published: “Plus Therapeutics leads healthcare gainers; Accuray and ReWalk Robotics among losers – Seeking Alpha” on August 16, 2019. More interesting news about Jaguar Health, Inc. (NASDAQ:JAGX) were released by: Benzinga.com and their article: “13 Healthcare Stocks Moving In Wednesday’s Pre-Market Session – Benzinga” published on August 28, 2019 as well as Streetinsider.com‘s news article titled: “Jaguar Health Promotes Jonathan Wolin to Chief of Staff, Chief Compliance Officer & General Counsel – StreetInsider.com” with publication date: September 09, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.